

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Janssen Pharmaceutica, N.V.	05/14/2004
RECEIVING PARTY DATA	
Name:	Tibotec Pharmaceuticals, Ltd.
Street Address:	Unit 4, Block 4B, Blanchardstown Corporate Park
City:	Blanchardstown 15
State/Country:	IRELAND
Postal Code:	Dublin
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10563691
CORRESPONDENCE DATA	
Fax Number:	(732)524-2808
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	732-524-3742
Email:	JNJUSPATENT@CORUS.JNJ.COM
Correspondent Name:	Philip S. Johnson, Esq.
Address Line 1:	One Johnson & Johnson Plaza
Address Line 4:	New Brunswick, NEW JERSEY 08933
ATTORNEY DOCKET NUMBER:	TIP-0064-USPCT
NAME OF SUBMITTER:	Theresa R. Watts
Total Attachments: 4 source=RecordationJanssenPharm2Tibotec4#page1.tif source=AssignJanssenPharmaceutica2Tibotec#page1.tif source=AssignJanssenPharmaceutica2Tibotec#page2.tif source=AssignJanssenPharmaceutica2Tibotec#page3.tif	

CH \$40.00 10563691

500546860

PATENT
REEL: 020983 FRAME: 0648

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s):

Janssen Pharmaceutica, N.V.

Execution Date(s) May 14, 2004 and February 23, 2005

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Tibotec Pharmaceuticals, Ltd.

Street Address:

Unit 4, Block 4B
Blanchardstown Corporate Park

City: Blanchardstown

State: 15 Dublin

Country: Ireland

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- | | |
|---|---|
| <input checked="" type="checkbox"/> Assignment | <input type="checkbox"/> Merger |
| <input type="checkbox"/> Security Agreement | <input type="checkbox"/> Change of Name |
| <input type="checkbox"/> Government Interest Assignment | |
| <input type="checkbox"/> Executive Order 9424, Confirmatory License | |
| <input type="checkbox"/> Other | |

4. Application or patent number(s): .

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

10/563,691

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Philip S. Johnson, Esq.
Chief Patent Counsel
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Phone: (732) 524-3742
Fax: (732) 524-2808
Email Address: JNJUSPATENT@CORUS.JNJ.COM

6. Total number of applications & patents involved:

1

7. Total fee (37 CFR 1.21(h) & 3.41) \$40.00

☐ Authorized to be charged to Deposit Account

8. Payment Information

Deposit Account Number: 10-0750/ /

9. Signature

/Mary A. Appollina/

Signature

May 22, 2008

Date

Mary A. Appollina
Name of Person Signing

Total number of pages including cover sheet,
attachments, and document: 4

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

General Assignment

WHEREAS, Janssen Pharmaceutica N.V. , having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter called "Assignor"), is the owner of certain new and useful inventions relating to

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

for which on the 30th day of April 2004, US Provisional Patent Application no. 60/567182 was filed at the USPTO.

WHEREAS, TIBOTEC PHARMACEUTICALS LTD., having its place of business at Little Island, Co Cork, Ireland (hereinafter called "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

I agree that this general assignment is effective from 30 April 2004.

IN TESTIMONY WHEREOF, Assignor has hereunto set his hand and seals this date.

For Janssen Pharmaceutica N.V.



.....

Signed this 23rd day of February 2005

General Assignment

WHEREAS, Janssen Pharmaceutica N.V. , having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter called "Assignor"), is the owner of certain new and useful inventions relating to

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

for which on the 26th day of October 2004, European Patent Application no. 04105312.5 was filed at the European Patent Office.

WHEREAS, TIBOTEC PHARMACEUTICALS LTD., having its place of business at Little Island, Co Cork, Ireland (hereinafter called "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

I agree that this general assignment is effective from 30 April 2004.

IN TESTIMONY WHEREOF, Assignor has hereunto set his hand and seals this date.

For Janssen Pharmaceutica N.V.



Signed this 23rd day of February 2005

Luc Quaghebeur
Proxy holder

General Assignment

WHEREAS, Janssen Pharmaceutica N.V. , having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter called "Assignor"), is the owner of certain new and useful inventions relating to

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION


for which on the 18th day of December 2003, European Patent Application no. 03104810.1 was filed at the European Patent Office.

WHEREAS, TIBOTEC PHARMACEUTICALS LTD., having its place of business at Unit 4, Block 4B, Blanchardstown Corporate Park, Blanchardstown, 15 Dublin, Ireland (hereinafter called "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

IN TESTIMONY WHEREOF, Assignor have hereunto set their hands and seals this
14th day of May, 2004.

For Janssen Pharmaceutica N.V.



Dirk COLLIER



PATENT